# Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by UK REACH Regulation SI 2019/758

# **SAFETY DATA SHEET**



UVILUX 6790-03 - TS 6868 WHITE

# SECTION 1: Identification of the substance/mixture and of the company/ undertaking

#### 1.1 Product identifier Product name

: UVILUX 6790-03 - TS 6868 WHITE

**1.2 Relevant identified uses of the substance or mixture and uses advised againstProduct use**: Paint.

#### 1.3 Details of the supplier of the safety data sheet

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

e-mail address of person : Prod-safe@teknos.com

# responsible for this SDS

#### National contact

Teknos (UK) Limited, 7 Longlands Rd, Bicester, Oxfordshire OX26 5AH, United Kingdom. Tel. +44 (0) 1869 208005.

#### **1.4 Emergency telephone number**

National advisory body/Poison Centre

Telephone number : NHS: 111

### **SECTION 2: Hazards identification**

#### 2.1 Classification of the substance or mixture

Product definition : Mixture

**Classification according to UK CLP/GHS** 

Skin Irrit. 2, H315 Eye Dam. 1, H318 Skin Sens. 1, H317 Aquatic Acute 1, H400 Aquatic Chronic 2, H411

The product is classified as hazardous according to UK CLP Regulation SI 2019/720 as amended.

Ingredients of unknown toxicity : 2.9 percent of the mixture consists of component(s) of unknown acute dermal toxicity 2.9 percent of the mixture consists of component(s) of unknown acute inhalation toxicity

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

#### 2.2 Label elements

Hazard pictograms



Signal word	: Danger
Hazard statements	<ul> <li>H315 - Causes skin irritation.</li> <li>H317 - May cause an allergic skin reaction.</li> <li>H318 - Causes serious eye damage.</li> </ul>

H410 - Very toxic to aquatic life with long lasting effects.

#### **Precautionary statements**

 Date of issue/Date of revision
 : 24/10/2022
 Date of previous issue
 : No previous validation
 Vi

 UVILUX 6790-03 - TS 6868 WHITE
 Lab

# **SECTION 2: Hazards identification**

Prevention	:	<ul> <li>P280 - Wear protective gloves. Wear eye or face protection.</li> <li>P273 - Avoid release to the environment.</li> <li>P261 - Avoid breathing vapour.</li> <li>P264 - Wash thoroughly after handling.</li> </ul>
Response	:	<ul> <li>P391 - Collect spillage.</li> <li>P362 + P364 - Take off contaminated clothing and wash it before reuse.</li> <li>P302 + P352 - IF ON SKIN: Wash with plenty of water.</li> <li>P333 + P313 - If skin irritation or rash occurs: Get medical advice or attention.</li> <li>P305 + P351 + P338, P310 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.</li> <li>Immediately call a POISON CENTER or doctor.</li> </ul>
Storage	1	Not applicable.
Disposal	:	P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.
Supplemental label elements	:	Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	:	Not applicable.
2.3 Other hazards		
Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII	:	This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
Other hazards which do not result in classification	:	None known.

# SECTION 3: Composition/information on ingredients

Hexamethylene diacrylate REACH #: 01-2119484737-2 EC: 235-921-9	≥25 - ≤50	Skin Irrit. 2, H315	[4]
CAS: 13048-33-4 Index: 607-109-00		Eye Irrit. 2, H319 Skin Sens. 1, H317 Aquatic Acute 1, H400 (M=1) Aquatic Chronic 2, H411	[1]
Dipropylenglycol diacrylate REACH #: 01-2119484629-2 EC: 260-754-3 CAS: 57472-68-1		Skin Irrit. 2, H315 Eye Dam. 1, H318 Skin Sens. 1, H317	[1]
Propylidynetrimethanol, ethoxylated, esters with acrylic acid EC: 500-066-5 CAS: 28961-43-5	30 ≤5	Eye Irrit. 2, H319 Skin Sens. 1, H317 Aquatic Chronic 3, H412	[1]
titanium dioxide REACH #: 01-2119489379-1 EC: 236-675-5 CAS: 13463-67-7	7 ≤5	Carc. 2, H351 (inhalation)	[1] [*]
4,4'-Isopropylidenediphenol, oligomeric reaction products with 1-chloro-2,3-epoxypropane, esters with acrylic acid	53 ≤5	Skin Sens. 1, H317	[1]
2-Propenoic acid, 1,1'-[(1-methyl- 1,2-ethanediyl)bis[oxy(methyl- 2,1-ethanediyl)]] ester, reaction CAS: 111497-86-		Skin Irrit. 2, H315 Eye Irrit. 2, H319 Skin Sens. 1B, H317	[1]

products with diethylamine		-		
2-hydroxy-2-methylpropiophenone	REACH #: 01-2119472306-39 EC: 231-272-0 CAS: 7473-98-5	≤5	Acute Tox. 4, H302 Aquatic Chronic 3, H412	[1]
(1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylate	REACH #: 01-2119484613-34 EC: 256-032-2 CAS: 42978-66-5 Index: 607-249-00-X	≤3	Skin Irrit. 2, H315 Eye Irrit. 2, H319 Skin Sens. 1, H317 STOT SE 3, H335 Aquatic Chronic 2, H411	[1]
Diphenyl(2,4,6-trimethylbenzoyl) phosphine oxide	REACH #: 01-2119972295-29 EC: 278-355-8 CAS: 75980-60-8 Index: 015-203-00-X	<3	Skin Sens. 1B, H317 Repr. 2, H361f (causing atrophy of the testes) Aquatic Chronic 2, H411	[1]
Fatty acids, C18-unsatd., dimers, polymers with acrylic acid, bisphenol A, epichlorohydrin and nonanoic acid	CAS: 216689-76-8	<1	Skin Sens. 1B, H317	[1]
Polyethylene wax	REACH #: 01-2119488076-30 EC: 232-315-6 CAS: 8002-74-2	≤1	Not classified.	[2]
2,6-di-tert-butyl-p-cresol	EC: 204-881-4 CAS: 128-37-0	<0.1	Aquatic Chronic 1, H410 (M=1)	[1] [2]
Cyclohexane	EC: 203-806-2 CAS: 110-82-7 Index: 601-017-00-1	<0.1	Flam. Liq. 2, H225 Skin Irrit. 2, H315 STOT SE 3, H336 Asp. Tox. 1, H304 Aquatic Acute 1, H400 (M=1) Aquatic Chronic 1, H410 (M=1)	[1] [2]
2,6-di-tert-butyl-p-cresol	REACH #: 01-2119565113-46 EC: 204-881-4 CAS: 128-37-0	<0.1	Aquatic Acute 1, H400 (M=1) Aquatic Chronic 1, H410 (M=1)	[1] [2]
			See Section 16 for the full text of the H statements declared above.	

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

<u>Type</u>

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

[\*] The classification as a carcinogen by inhalation applies only to mixtures placed on the market in powder form containing 1% or more of titanium dioxide particles with aerodynamic diameter  $\leq$  10 µm not bound within a matrix.

Occupational exposure limits, if available, are listed in Section 8.

### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

#### Eye contact

: Get medical attention immediately. Call a poison center or physician. Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Chemical burns must be treated promptly by a physician.

#### SECTION A. EIM et aid moasuros

SECTION 4: FIrst ald		leasures
Inhalation	:	Get medical attention immediately. Call a poison center or physician. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
Skin contact	:	Get medical attention immediately. Call a poison center or physician. Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Chemical burns must be treated promptly by a physician. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.
Ingestion	:	Get medical attention immediately. Call a poison center or physician. Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Chemical burns must be treated promptly by a physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Protection of first-aiders	:	No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

#### 4.2 Most important symptoms and effects, both acute and delayed

Over-exposure signs/s	<u>ymptoms</u>
Eye contact	: Adverse symptoms may include the following: pain watering redness
Inhalation	: No specific data.
Skin contact	: Adverse symptoms may include the following: pain or irritation redness blistering may occur
Ingestion	: Adverse symptoms may include the following: stomach pains
4.3 Indication of any imr	nediate medical attention and special treatment needed
Notes to physician	<ul> <li>In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.</li> </ul>

#### Specific treatments : No specific treatment.

# **SECTION 5: Firefighting measures**

5.1 Extinguishing media		
Suitable extinguishing media	:	Use an extinguishing agent suitable for the surrounding fire.
Unsuitable extinguishing media	:	None known.

# **SECTION 5: Firefighting measures**

5.2 Special hazards arising fi	om the substance or mixture
Hazards from the substance or mixture	: In a fire or if heated, a pressure increase will occur and the container may burst. This material is very toxic to aquatic life. This material is toxic to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.
Hazardous combustion products	: Decomposition products may include the following materials: carbon dioxide carbon monoxide nitrogen oxides phosphorus oxides halogenated compounds metal oxide/oxides
5.3 Advice for firefighters	
Special protective actions for fire-fighters	: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
Special protective equipment for fire-fighters	<ul> <li>Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.</li> </ul>

# **SECTION 6: Accidental release measures**

6.1 Personal precautions, pro	teo	ctive equipment and emergency procedures
For non-emergency personnel	:	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Do not breathe vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
For emergency responders	:	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
6.2 Environmental precautions	:	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities. Collect spillage.
6.3 Methods and material for	со	ntainment and cleaning up
Small spill	:	Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Large spill	:	Stop leak if without risk. Move containers from spill area. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations (see Section 13). Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilt product. Note: see Section 1 for emergency contact information and Section 13 for waste disposal.
6.4 Reference to other sections	:	See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

# **SECTION 7: Handling and storage**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 7.1 Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Do not get in eyes or on skin or clothing. Do not breathe vapour or mist. Do not ingest. Avoid release to the environment. If during normal use the material presents a respiratory hazard, use only with adequate ventilation or wear appropriate respirator. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

#### 7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.

#### **Seveso Directive - Reporting thresholds**

Danger criteria		
	Notification and MAPP threshold	Safety report threshold
E1	100 tonne	200 tonne

#### 7.3 Specific end use(s) Recommendations

: Not available.

Industrial sector specific

: Not available.

solutions

SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational exposure limits

Polyethylene wax	EH40/2005 WELs (United Kingdom (UK), 1/2020). STEL: 6 mg/m <sup>3</sup> 15 minutes. Form: Fume
	TWA: 2 mg/m <sup>3</sup> 8 hours. Form: Fume
2,6-di-tert-butyl-p-cresol	EH40/2005 WELs (United Kingdom (UK), 1/2020).
	TWA: 10 mg/m³ 8 hours.
Cyclohexane	EH40/2005 WELs (United Kingdom (UK), 1/2020).
	STEL: 1050 mg/m <sup>3</sup> 15 minutes.
	STEL: 300 ppm 15 minutes.
	TWA: 100 ppm 8 hours.
	TWA: 350 mg/m <sup>3</sup> 8 hours.
2,6-di-tert-butyl-p-cresol	EH40/2005 WELs (United Kingdom (UK), 1/2020).
	TWA: 10 mg/m³ 8 hours.
Recommended monitoring procedures	: If this product contains ingredients with exposure limits, personal, workplace atmosphere or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to appropriate monitoring standards. Reference to national guidance documents for methods for the determination of hazardous substances will also be required.
DNELs/DMELs	
Date of issue/Date of revision	: 24/10/2022 Date of previous issue : No previous validation Version : 1 6/18
JVILUX 6790-03 - TS 6868 WI	HITE Label No :40584

NEL         Long term Oral DNEL         Long term Oral Long term Dermal         2.08 mg/L 2.48 mg/ Linhalation         Oppulation Population         Systemic Systemic Population           Dipropylenglycol diacrylate         DNEL         Long term Dermal         7.2 mg/m <sup>2</sup> General General         Systemic Population           Dipropylenglycol diacrylate         DNEL         Long term Oral         2.08 mg/L 2.07 mg/ <sup>2</sup> General         Systemic Population           Dipropylenglycol diacrylate         DNEL         Long term Oral         2.08 mg/L 2.08 mg/L 2.09 genr         General         Systemic Population           DNEL         Long term Oral         Long term Oral         General         Systemic Population         Systemic Population           DNEL         Long term Oral         Long term Oral         Systemic Population         Systemic Population         Systemic Population           Propylidynetrimethanol, ethoxylated, esters with acrylic acid         DNEL         Long term Oral         0.5 mg/L Population         General Population         Systemic Population           DNEL         Long term Oral         0.5 mg/L Population         General Population         Systemic Population           DNEL         Long term Oral         1.4 mg/L Population         Systemic Population         Systemic Population           1.4.1 sopropylidenediphenol, oligomeir creaction p	Product/ingredient name	Туре	Exposure	Value	Population	Effect	S
DNEL Dipropylenglycol diacrylateDNEL DNEL Long term Dermal Long term Dermal DNEL Long term Dermal Long term Dermal DNEL Long term DNEL Long term DNEL 	Hexamethylene diacrylate	DNEL	Long term Dermal	1.66 mg/	General	Systemic	
Variable         Kg bw/day (X7 mg/ (kg bw/day)         population (X6 kg bw/day)         population (X6 kg bw/day)           Dipropylenglycol diacrytate         DNEL         Long term (Inhalation)         7.2 mg/m         General (S9 kw/day)         Systemic (General)           Dipropylenglycol diacrytate         DNEL         Long term Dermal         1.66 mg/ (S9 kw/day)         General (General)         Systemic (General)           Dipropylenglycol diacrytate         DNEL         Long term Dermal         2.44 mg/m         General (General)         Systemic (General)           DNEL         Long term Dermal         2.44 mg/m         General (General)         Systemic (General)         Systemic (G							
DNELLong term Dermal Long term2.77 mg/ 24.48 mg/ WorkersWorkersSystemic systemic populationDipropylenglycol diacrylateDNELLong term7.2 mg/m³General populationSystemic populationDipropylenglycol diacrylateDNELLong term Oral1.66 mg/ kg bw/dayGeneral populationSystemic populationDipropylenglycol diacrylateDNELLong term Oral2.68 mg/ kg bw/dayGeneral populationSystemic populationPropylidynetrimethanol, ethoxylated, esters with acrylic acidDNELLong term Dermal thatation7.24 mg/m² (General populationGeneral populationSystemic populationPropylidynetrimethanol, ethoxylated, esters with acrylic acidDNELLong term Dermal thatation0.5 mg/kg (General populationGeneral populationSystemic populationDNELLong term thatation0.6 mg/kg (General populationGeneral populationSystemic populationDNELLong term thatation1.4 mg/kg (General populationGeneral systemic populationSystemic population4.4'-Isopropylidenediphenol, oligomeric reaction products with 1_2-ethanediyl)bis[cox/(methyl- 2_1-ethanediyl)bis[cox/(methyl- 2_1-ethanediyl)bis[cox/ (methyl-2_1-ethanediyl)bis[cox/ (methyl-2_1-ethanediyl)bis[cox/ (methyl-2_1-ethanediyl)bis[cox/ (methyl-2_1-ethanediyl)bis[cox/ (methyl-2_1-ethanediyl)bis[cox/ (methyl-2_1-ethanediyl)bis[cox/ (methyl-2_1-ethanediyl)bis[cox/ (methyl-2_1-ethanediyl)bis[cox/ (methyl-2_1-ethanediyl)bis[cox/ (methyl-2_1-ethanediyl)bis[cox/ <td></td> <td>DNEL</td> <td>Long term Oral</td> <td></td> <td></td> <td>Systemic</td> <td></td>		DNEL	Long term Oral			Systemic	
Volume         Kg bw/day (A 48 mg/m)         Vorkers (A 48 mg/m)         Systemic (A 48 mg/m)           Dipropylenglycol diacrylate         DNEL (Dipropylenglycol diacrylate         DNEL (Dipropylenglycol diacrylate         DNEL (Dipropylenglycol diacrylate         Cong term (Dipropylenglycol diacrylate)         Systemic (Dipropylenglycol diacrylate)			Long torm Dormal			Systemic	
DNEL Dipropylenglycol diacrylateDNEL DNEL Long termCong term (Inhalation (Inhalation DNEL Long term Oral DNEL Long term Oral 		DNEL	Long term Denna		VUINEIS	Systemic	
Dipropylenglycol diacrylateInhalationm³CDipropylenglycol diacrylateDNELLong term Dermal1.66 mg/ topulationGeneral populationSystemic populationDipropylenglycol diacrylateDNELLong term Oral2.08 mg/ 		DNEL	Long term		Workers	Systemic	
Dipropylenglycol diacrylate Dipropylenglycol				m³		,	
Dipropylenglycol diacrylateDNELLong term Dermal1.66 mg/ kg bw/dayGeneral opulation General opulationSystemic opulationDNELLong term Oral2.08 mg/ kg bw/dayCeneral opulationSystemic opulationDNELLong term Dermal2.77 mg/ kg bw/dayGeneral opulationSystemic motalationPropylidynetrimethanol, ethoxytated, esters with acrylic acidDNELLong term Dermal0.5 mg/kg bw/dayGeneral opulationSystemic maintationDNELLong term Oral0.8 mg/kg bw/dayGeneral opulationSystemic opulationDNELLong term Oral1.4 mg/kg bw/dayGeneral opulationSystemic opulationDNELLong term Oral1.4 mg/kg bw/dayGeneral opulationSystemic opulationDNELLong term Oral1.6 mg/kg bw/dayGeneral opulationSystemic opulationDNELLong term Oral10 mg/m3WorkersSystemic opulationLohor czrDNELLong term Oral10 mg/m3WorkersSystemic opulationLohor czrDNELLong term Dermal1.75 mg/ kg bw/dayWorkersSystemic opulationLohor czrDNELLong term Dermal1.17 mg/m3WorkersSystemic opulationLohor czrDNELLong term Dermal3.33 mg/ kg bw/dayWorkersSystemic opulation2-Propenoic acid, 1, 1'-{(1-methyl- 1,2-ethanediy)bis[oxy(methyl- 2,1-ethanediy)bis[oxyDNELLong term Dermal inhalatio		DNEL		7.2 mg/m³		Systemic	
Propylidynetrimethanol, ethoxylated, esters with acrylic acid     DNEL DNEL     Long term Oral Long term Dermal     Kg bw/day 2.77 mg/ Xg bw/day     population population     Systemic population       Propylidynetrimethanol, ethoxylated, esters with acrylic acid     DNEL     Long term Dermal     7.24 mg/m <sup>2</sup> General population     Systemic population       DNEL     Long term Dermal     0.5 mg/kg     General population     Systemic population       DNEL     Long term Dermal     0.8 mg/kg     General population     Systemic population       DNEL     Long term Dermal     0.8 mg/kg     General population     Systemic population       DNEL     Long term Oral     1.4 mg/kg     General population     Systemic population       DNEL     Long term     16.2 mg/m <sup>3</sup> General population     Systemic population       DNEL     Long term     10 mg/m <sup>3</sup> Workers     Systemic population       DNEL     Long term     10 mg/m <sup>3</sup> Workers     Systemic       1-choro-2.3 epoxypropane, esters with acrylic acid     DNEL     Long term Oral     1.33 mg/ workers     Workers     Systemic       2-hydroxy-2-methylpropiophenone     DNEL     Long term Oral     0.4 mg/kg     General population     Systemic       DNEL     Long term Oral     0.4 mg/kg     General population     Systemic       2-hydro	Nin manual an aile an la dia am da ta			1.00		O. un tra maile	
Propylidynetrimethanol, ethoxylated, esters with acrylic acidDNEL DNELLong term Long term DNEL2.08 mg/kg bw/day 2.77 mg/ mgGeneral population WorkersSystemic populationPropylidynetrimethanol, ethoxylated, esters with acrylic acidDNEL DNELLong term Inhalation7.24 mg/m³ DNELGeneral populationSystemic populationPropylidynetrimethanol, ethoxylated, esters with acrylic acidDNEL DNELLong term Dermal Inhalation0.5 mg/kg DNELGeneral populationSystemic populationDNEL Long term InhalationDNEL DNELLong term Oral Inhalation1.4 mg/kg populationGeneral populationSystemic populationDNEL Long term InhalationDNEL Long term Inhalation10 mg/m³ To mg/m³WorkersSystemic populationA.4'-Isopropylidenediphenol, oligomeric reaction products with 1-chloro-2,3-epoxypropane, esters with acrylic acidDNEL DNEL Long term Inhalation10 mg/m³ To mg/m³WorkersSystemic populationDNEL Long term products with diethylamineDNEL DNEL Long term Dermal1.17 mg/m³ NorkersWorkersSystemic population2-hydroxy-2-methylpropiophenone products with diethylamineDNEL DNEL Long term Dermal1.17 mg/m³ NorkersWorkersSystemic population1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)bis[oxyDNEL DNEL Long term Dermal1 mg/kg bw/dayGeneral population gopulationSystemic population <td>Dipropylenglycol diacrylate</td> <td>DNEL</td> <td>Long term Dermai</td> <td></td> <td></td> <td>Systemic</td> <td></td>	Dipropylenglycol diacrylate	DNEL	Long term Dermai			Systemic	
Propylidynetrimethanol, ethoxylated, esters with acrylic acidDNEL UNELLong term Dermal Long term Dermalkg bw/day 2.77 mg/ kg bw/dayPropyliation opulation gopulation m*Systemic population my WorkersSystemic systemic populationPropylidynetrimethanol, ethoxylated, esters with acrylic acidDNEL DNELLong term Dermal Inhalation0.5 mg/kg bw/dayGeneral populationSystemic populationDNEL Long term DermalDNEL Long term Dermal0.8 mg/kg bw/dayWorkersSystemic populationDNEL Long term OralDNEL Long term Oral0.8 mg/kg bw/dayGeneral populationSystemic populationUtanium dioxideDNEL Long term InhalationDNEL Long term Inhalation10 mg/m3 WorkersGeneral populationSystemic populationUtanium dioxideDNEL Long term InhalationDNEL Long term Oral10 mg/m3 WorkersWorkersSystemic systemic populationUtanium dioxideDNEL Long term OralDNEL InhalationLong term Inhalation1.17 mg/m3 WorkersWorkersSystemic systemic moducts with 1-choro-2,3-epoxypropane, esters with acrylic acidDNEL Long term Dermal1.17 mg/m3 S.33 mg/ WorkersWorkersSystemic systemic population2-hydroxy-2-methylpropiophenoneDNEL Long term DermalLong term Dermal 0.5 mg/kg bw/day0.5 mg/kg General populationSystemic systemic moducts with 1-chored/by/kg DNEL Long term Dermal1 mg/kg bw/dayWorkers<		DNEL	Long term Oral			Systemic	
Propylidynetrimethanol, ethoxylated, esters with acrylic acidDNEL Long term InhalationLong term (7.24 mg/m2)VorkersSystemic populationPropylidynetrimethanol, ethoxylated, esters with acrylic acidDNEL DNEL Long term DNEL Long term Dermal0.5 mg/kg bw/dayGeneral populationSystemic populationDNEL bw/dayDNEL DNEL DNEL Long term Oral0.4 mg/kg bw/dayGeneral populationSystemic populationDNEL bw/dayDNEL DNEL DNEL Long term Oral1.4 mg/kg bw/dayGeneral populationSystemic populationDNEL bw/dayDNEL DNEL Long term Inhalation DNEL Long term Inhalation1.6.2 mg/m3 TO mg/m3 WorkersSystemic population4.4'-Isopropylidenediphenol, oligomeric reaction products with 1-chloro-2,3-epoxypropane, esters with acrylic acidDNEL DNEL Long term DNEL Long term Dermal10 mg/m3 TO mg/m3 WorkersWorkersSystemic population2-Propenoic acid, 1,1'-[(1-methyl- 1,2-ethanediyl)bis[oxy(methyl- 2,1-ethanediyl)bis[oxy(methyl- 2,1-ethanediyl)bis[oxy(methyl- 2,1-ethanediyl)bis[oxy(methyl- 2,1-ethanediyl)bis[oxy (methyl-1,2-ethanediyl)bis[oxy (methyl-1,2-ethanediyl)bis[oxy (methyl-1,2-ethanediyl)bis[oxy (methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)bis[oxyDNEL DNELLong term Dermal DNEL Long term Dermal1 mg/kg bw/dayWorkersSystemic population general population0NEL Long term InhalationDNEL Long term Dermal1 mg/kg bw/dayWorkersSyste		DITEE	Long tonn ordi			eyetenne	
Propylidynetrimethanol, ethoxylated, esters with acrylic acidDNEL Long term InhalationLong term perm 24.48 mg/ m³7.24 mg/m³ population WorkersSystemic populationPropylidynetrimethanol, ethoxylated, esters with acrylic acidDNEL Long term Dermal0.8 mg/kg bw/dayGeneral populationSystemic populationDNEL Long term Oral0.8 mg/kg bw/dayGeneral populationSystemic populationDNEL Long term Oral0.8 mg/kg bw/dayGeneral populationSystemic populationDNEL Long term Oral0.8 mg/kg bw/dayGeneral populationSystemic populationDNEL Long term Oral0.8 mg/kg bw/dayGeneral populationSystemic populationDNEL Long term OralDNEL Long term Oral10 mg/m³ WorkersWorkersSystemic population4.4'-Isopropylidenediphenol, oligomeric reaction products with 1.2-ethanediylijs[oxy(methyl- 2.1-ethanediylijs[oxy(methyl- 2.1-ethanediylijs[oxy(methyl- populationDNEL DNEL Long term Oral1.17 mg/m³ WorkersWorkersSystemic population2-hydroxy-2-methylpropiophenoneDNEL DNEL Long term OralLong term Oral 0.4 mg/kg bw/day0.4 mg/kg General general gopulationSystemic population2-hydroxy-2-methylpropiophenoneDNEL Long term OralLong term Oral 0.4 mg/kg bw/dayWorkers General general gopulationSystemic population2-hydroxy-2-methylpropiophenoneDNEL Long term OralLong term Oral 0.4 mg/kg general populat		DNEL	Long term Dermal			Systemic	
Propylidynetrimethanol, ethoxylated, esters with acrylic acidInhalation Long term Dermal24.48 mg/ m²WorkersSystemic populationPropylidynetrimethanol, ethoxylated, esters with acrylic acidDNELLong term Dermal0.5 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Oral1.4 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Oral1.4 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Inhalation16.2 mg/m²WorkersSystemic populationA.4'-Isopropylidenediphenol, oligomeric reaction products with 1-chior-2,3-epoxypropane, esters with acrylic acidDNELLong term DNEL10 mg/m² T.5 mg/ kg bw/dayGeneral populationSystemic population2Propenoic acid, 1, 1'-[(1-methyl- 1,2-ethanediyl)bis[oxy(methyl- 2-hydroxy-2-methylpropiophenoneDNELLong term DNEL1.17 mg/m² MorkersWorkersSystemic bw/dayDNELLong term Dermal Inhalation1.17 mg/m² m²WorkersSystemic bw/day2-hydroxy-2-methylpropiophenoneDNELLong term Dermal Inhalation3.33 mg/ m² GeneralWorkersSystemic populationDNELLong term Dermal Inhalation0.4 mg/kg m²General Systemic populationSystemic systemic m²2-hydroxy-2-methylpropiophenoneDNELLong term Dermal Inhalation0.4 mg/kg m²General Systemic populationDNELLong term Dermal Inhal							
Propylidynetrimethanol, ethoxylated, esters with acrylic acidDNELLong term Long term Dermal24,48 mg/ m <sup>3</sup> WorkersSystemic SystemicDNELLong term Dermal0.8 mg/kg bw/dayGeneral bw/dayGeneral populationSystemic bw/dayDNELLong term Oral1.4 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Oral1.4 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Inhalation16.2 mg/m³General populationSystemic populationDNELLong term Inhalation10 mg/m³ bw/dayGeneral populationSystemic population4.4'-Isopropylidenediphenol, oligomeric reaction products with 1.2-ethanediyl)bis[oxy(methyl- 2.1-ethanediyl)jis[extre reaction products with diethylamineDNELLong term Dermal Inhalation1.17 mg/m³ m³WorkersSystemic populationDNELLong term Oral Inhalation1.17 mg/m³ kg bw/dayWorkersSystemic population2-hydroxy-2-methylpropiophenoneDNELLong term Oral Inhalation1.17 mg/m³ m³WorkersSystemic populationDNELLong term Oral Inhalation0.4 mg/kg general populationGeneral populationSystemic population2-hydroxy-2-methylpropiophenoneDNEL InhalationLong term Oral Inhalation0.4 mg/kg general populationGeneral populationSystemic population0.1DNEL InhalationLong term Oral Inhalation0.4		DNEL		7.24 mg/m <sup>3</sup>		Systemic	
Propylidynetrimethanol, ethoxylated, esters with acrylic acidDNEL DNELInhalation Long term Dermalm³ 0.5 mg/kg bw/dayGeneral population goneral populationSystemic Systemic populationtitanium dioxideDNEL UNELLong term Oral1.4 mg/kg bw/dayGeneral goneral populationSystemic systemic populationtitanium dioxideDNEL UNELLong term Inhalation16.2 mg/m³WorkersSystemic goneral population4.4'-Isopropylidenediphenol, oligomeric reaction products with 1-chloro-2,3-epoxypropane, esters with acrylic acidDNEL DNELLong term Inhalation10 mg/m³WorkersSystemic population2-Propenoic acid, 1,1'-[(1-methyl- 1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)bis[oxy (methyl-1,2-ethanediyl)bis[oxyDNEL DNELLong term Inhalation1.17 mg/m³ UNKEWorkersSystemic bw/dayDNEL (1-methyl-1,2-ethanediyl)bis[oxy (methyl-1,2-ethanediyl)bis[oxyDNEL DNELLong term Dermal Inhalation3.3 mg/ UNKEWorkersSystemic population(1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)bis[oxyDNEL DNELLong term Dermal Inhalation3.5 mg/m³WorkersSystemic population(1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)bis[oxyDNEL DNELLong term Dermal Inhalation1 mg/kg Boreral DNELWorkersSystemic population(1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)bis[oxyDNEL DNELLong term Dermal Inhalation <td></td> <td></td> <td></td> <td>24.48 mg/</td> <td></td> <td>Systemic</td> <td></td>				24.48 mg/		Systemic	
Propylidynetrimethanol, ethoxylated, esters with acrylic acidDNEL DNELLong term Dermal Long term Dermal0.5 mg/kg bw/dayGeneral opolutionSystemic SystemicDNEL bulkdayDNEL DNELLong term Oral1.4 mg/kg bw/dayGeneral opolutionSystemic populationDNEL titanium dioxideDNEL DNELLong term Inhalation1.6.2 mg/m³ BorlinhalationGeneral populationSystemic population4,4'-Isopropylidenediphenol, oligomeric reaction products with 12-herhanediyl)bis[oxy(methyl- 2,1-ethanediyl)bis[oxy(methyl- 2,-hydroxy-2-methylpropiophenoneDNEL DNELLong term Inhalation1.17 mg/m³ BorlinhalationWorkersSystemic SystemicDNEL DNELDNEL Long term DermalLong term Inhalation1.17 mg/m³ BorlinhalationWorkersSystemic Systemic2-Propenoic acid, 1,1'-[(1-methyl- 1,2-ethanediyl)bis[oxy(methyl- 2,1-ethanediyl)bis[oxy(methyl- 2,1-ethanediyl)bis[oxyDNEL DNELLong term Long term Dermal3.33 mg/ BorlinhalationWorkersSystemic Systemic0.5 mg/kg (methyl-1,2-ethanediyl)bis[oxyDNEL DNELLong term Dermal Inhalation0.4 mg/kg BorlinhalationGeneral populationSystemic Systemic0.4 mg/kg (nthalationDNEL Long term Dermal0.4 mg/kg BorlinhalationGeneral populationSystemic Systemic2-hydroxy-2-methylpropiophenomeDNEL Long term DermalLong term Dermal DNEL Long term Dermal0.4 mg/kg BorlinhalationGeneral Systemic Systemic(1		DINLL	5		WOIKEIS	Systemic	
esters with acrylic acid DNEL	Propylidynetrimethanol, ethoxylated,	DNEL			General	Systemic	
bw/daybw/dayDNELLong term Oralbw/dayLong term1.4 mg/kgDNELLong termInhalationDNELLong termInhalationDNELLong termInhalationDNELLong termInhalationDNELLong termInhalationDNELLong termInhalationDNELLong termInhalationDNELLong termInhalationDNELLong term OralOng termInhalationDNELLong term Oral700 mg/kgGeneralSystemicJong term oralNorkersLong term oralNorkersDNELLong term DermalInhalationDNELLong term oral1.17 mg/m³WorkersSystemicDNELLong term Dermal1.2-ethanediyl)bis[oxy(methyl-2-hydroxy-2-methylpropiophenoneDNELDNELLong term DermalDNELLong term Dermal <td>esters with acrylic acid</td> <td></td> <td></td> <td>bw/day</td> <td></td> <td></td> <td></td>	esters with acrylic acid			bw/day			
DNELLong term Oral1.4 mg/kg bw/dayGeneral opulationSystemic opulationtitanium dioxideDNELLong term Inhalation4.9 mg/m³General opulationSystemic populationtitanium dioxideDNELLong term Inhalation16.2 mg/m³WorkersLocalDNELLong term Inhalation10 mg/m³WorkersLocalDNELLong term Oral700 mg/kg bw/dayGeneral populationSystemic population4.4'-Isopropylidenediphenol, oligometic reaction products with 1-chloro-2,3-epoxypropane, estersDNELLong term Oral700 mg/kg bw/dayGeneral populationSystemic population2.Propenoic acid, 1,1'-[(1-methyl-1,2-ethanediyl)bis[oxy (methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)bis[oxy (methy		DNEL	Long term Dermal		Workers	Systemic	
bw/daypopulationbw/daypopulationbw/daygeneralbw/daypopulationbw/daychancebw/day </td <td></td> <td></td> <td>Long torm Oral</td> <td></td> <td>Conorol</td> <td>Svotomio</td> <td></td>			Long torm Oral		Conorol	Svotomio	
DNELLong term Inhalation4.9 mg/m³General populationSystemictitanium dioxideDNELLong term Inhalation16.2 mg/m³WorkersSystemic4.4'-Isopropylidenediphenol, oligometic reaction products with 1-chloro-2,3-epoxypropane, estersDNELLong term Oral700 mg/kg bw/dayGeneral populationSystemic2-Propenoic acid, 1,1'-[(1-methyl- 1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)bis[oxyDNEL Long term Dermal Long te		DNEL	Long term Orai			Systemic	
Inhalation Long term Inhalationpopulation WorkersSystemic Systemic4,4'-Isopropylidenediphenol, oligomeric reaction products with 1-chloro-2,3-epoxypropane, estersDNELLong term Inhalation10 mg/m³WorkersLocalDNELLong term Oral700 mg/kg bw/dayGeneral populationSystemic2-Propenoic acid, 1,1'-[(1-methyl- 1,2-ethanediyl)bis[oxy(methyl- 2,1-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)bis[oxy (met		DNEL	Long term			Svstemic	
Inhalation Long term Inhalation10 mg/m³WorkersLocal4,4'-Isopropylidenediphenol, oligomeric reaction products with 1-chloro-2,3-epoxypropane, esters with acrylic acidDNELLong term Oral700 mg/kg bw/dayGeneral population WorkersSystemic bw/day2-Propenoic acid, 1,1'-[(1-methyl- 1,2-ethanediyl)bis[oxy(methyl- 2,1-ethanediyl)]] ester, reaction products with diethylamineDNELLong term Inhalation Long term Dermal1.17 mg/m³ WorkersWorkersSystemic SystemicDNELDNELLong term Inhalation Long term Dermal3.33 mg/ kg bw/dayWorkersSystemic Systemic2-hydroxy-2-methylpropiophenoneDNELLong term Dermal Inhalation DNEL0.4 mg/kg Beneral bw/dayGeneral Systemic Bow/daySystemic Systemic0.1DNELLong term Dermal Inhalation0.4 mg/kg Beneral Bow/dayGeneral SystemicSystemic Systemic2-hydroxy-2-methylpropiophenoneDNELLong term Dermal Inhalation0.4 mg/kg Beneral Bow/dayGeneral Systemic0DNELLong term Dermal Inhalation0.9 mg/m³ Beneral Bow/daySystemic Systemic0DNELLong term Dermal Inhalation3.5 mg/m³ Bow/daySystemic Systemic0DNELLong term Dermal1 mg/kg Bow/daySystemic Systemic0DNELLong term Dermal1 mg/kg Bow/daySystemic Systemic0DNELLong term Dermal1 mg/kg Bow/daySystemic Systemic<				- <b>U</b>		,	
titanium dioxideDNELLong term10 mg/m³WorkersLocal4,4'-Isopropylidenediphenol, oligomeric reaction products with 1-chloro-2,3-epoxypropane, esters with acrylic acidDNELLong term Oral700 mg/kg bw/dayGeneral populationSystemic2-Propenoic acid, 1,1'-[(1-methyl- 1,2-ethanediyl)bis[oxy(methyl- 2-hydroxy-2-methylpropiophenoneDNELLong term Inhalation1.17 mg/m³WorkersSystemicDNELDNELLong term Inhalation1.17 mg/m³WorkersSystemic2-Propenoic acid, 1,1'-[(1-methyl- 1,2-ethanediyl)bis[oxy(methyl- 2,1-ethanediyl)]] ester, reaction products with diethylamineDNELLong term Inhalation3.33 mg/ kg bw/dayWorkersSystemicDNELDNELLong term Oral0.4 mg/kg bw/dayGeneral populationSystemicDNELLong term Inhalation0.9 mg/m³General populationSystemicDNELLong term Inhalation0.9 mg/m³General populationSystemic0.1DNELLong term Inhalation3.5 mg/m³WorkersSystemic0.1DNELLong term Dermal1 mg/kg bw/dayWorkersSystemic0.1DNELLong term Dermal1 mg/kg bw/dayWorkersSystemic0.1DNELLong term Dermal1 mg/kg bw/daySystemicSystemic0.1DNELLong term Dermal1 mg/kg bw/daySystemicSystemic0.1DNELLong term Dermal1 mg/kg bw/dayGene		DNEL		16.2 mg/m <sup>3</sup>	Workers	Systemic	
4,4'-Isopropylidenediphenol, oligomeric reaction products with 1-chloro-2,3-epoxypropane, esters with acrylic acidDNELInhalation Long term Oral700 mg/kg bw/dayGeneral populationSystemic2-Propenoic acid, 1,1'-[(1-methyl- 1,2-ethanediyl)bis[oxy(methyl- 2,1-ethanediyl)]] ester, reaction products with diethylamineDNELLong term Inhalation1.17 mg/m³WorkersSystemicDNELLong term Inhalation1.17 mg/m³WorkersSystemic2-hydroxy-2-methylpropiophenoneDNELLong term Inhalation3.33 mg/ NELWorkersSystemicDNELLong term Dermal0.4 mg/kg bw/dayGeneral opulationSystemicDNELLong term Dermal0.4 mg/kg bw/dayGeneral opulationSystemic populationDNELLong term Dermal0.5 mg/kg bw/dayGeneral opulationSystemic population0.1 methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylateDNELLong term Dermal Inhalation3.5 mg/m³WorkersSystemic population(1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylateDNELLong term Dermal Inhalation1 mg/kg bw/dayWorkersSystemic Systemic population(1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylateDNELLong term Dermal Inhalation1 mg/kg bw/dayWorkersSystemic Systemic Systemic(1-methyl-1,2-ethanediyl)] diacrylateDNELLong term Dermal Inhalation1 mg/kg bw/dayWorkersSystemic Systemic <t< td=""><td>the set of the set of the</td><td></td><td></td><td>10</td><td>14/</td><td></td><td></td></t<>	the set of the set of the			10	14/		
A,4'-Isopropylidenediphenol, oligomeric reaction products with 1-chloro-2,3-epoxypropane, esters with acrylic acidDNELLong term Dermal700 mg/kg bw/dayGeneral populationSystemic2-Propenoic acid, 1,1'-[(1-methyl- 1,2-ethanediyl)bis[oxy(methyl- 2,1-ethanediyl)]] ester, reaction products with diethylamineDNELLong term Inhalation1.17 mg/m³WorkersSystemicDNELDNELLong term Dermal Inhalation3.33 mg/ kg bw/dayWorkersSystemic2-hydroxy-2-methylpropiophenoneDNELLong term Oral0.4 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.5 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.5 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.9 mg/m³ BonetSystemicDNELLong term Dermal0.9 mg/m³ bw/dayGeneral populationSystemicDNELLong term Dermal3.5 mg/m³ bw/daySystemicDNELLong term Dermal1.66 mg/ bw/daySystemicDNELLong term Dermal1.66 mg/ bw/daySystemicDNELLong term Dermal1.66 mg/ bw/daySystemicDNELLong term Dermal1.66 mg/ bw/daySystemicDNELLong term Dermal1.66 mg/ bw/dayGeneral bw/dayDNELLong term Dermal1.66 mg/ bw/dayGeneral bw/dayDNELLong term Dermal1.66 mg/ bw/dayGeneral bw/day <td>Itanium dioxide</td> <td>DNEL</td> <td></td> <td>10 mg/m<sup>3</sup></td> <td>vvorkers</td> <td>Local</td> <td></td>	Itanium dioxide	DNEL		10 mg/m <sup>3</sup>	vvorkers	Local	
4,4'-Isopropylidenediphenol, oligomeric reaction products with 1-chloro-2,3-epoxypropane, esters with acrylic acidDNELLong term Dermalbw/day 17.5 mg/ kg bw/daypopulation WorkersSystemic2-Propenoic acid, 1,1'-[(1-methyl- 1,2-ethanediyl)bis[oxy(methyl- 2,1-ethanediyl)bis[oxy(methyl- 2-hydroxy-2-methylpropiophenoneDNELLong term Inhalation Long term Oral1.17 mg/m³ 3.33 mg/ kg bw/dayWorkersSystemic2-hydroxy-2-methylpropiophenoneDNELLong term Oral Inhalation DNEL0.4 mg/kg bw/dayGeneral populationSystemic0.1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylateDNELLong term Dermal Long term Dermal0.5 mg/kg bw/dayGeneral populationSystemic Systemic(1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylateDNELLong term Dermal Long term Dermal1 mg/kg bw/dayWorkersSystemic Systemic0.1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylateDNELLong term Dermal Long term Dermal1 mg/kg bw/dayWorkersSystemic Systemic0.1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylateDNELLong term Dermal Long term Dermal1 mg/kg bw/daySystemic Systemic0.1-methyl-1,2-ethanediyl)DNELLong term Dermal Long term Dermal1 mg/kg bw/daySystemic Systemic0.1-methyl-2,1-ethanediyl)DNELLong term Dermal Long term Dermal1 mg/kg Bw/daySystemic Systemic<				700 ma/ka	General	Systemic	
4,4'-Isopropylidenediphenol, oligomeric reaction products with 1-chloro-2,3-epoxypropane, esters with acrylic acid 2-Propenoic acid, 1,1'-[(1-methyl- 1,2-ethanediyl)bis[oxy(methyl- 2,1-ethanediyl)]] ester, reaction products with diethylamine 2-hydroxy-2-methylpropiophenone (1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylate (1-methyl-1,2-ethanediyl)] diacrylate DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNE		DILL	Long torm ordi			Cysternie	
1-chloro-2,3-epoxypropane, esters with acrylic acidDNELLong term Inhalation1.17 mg/m³WorkersSystemic2-Propenoic acid, 1,1'-[(1-methyl- 1,2-ethanediyl)bis[oxy(methyl- 2,1-ethanediyl)]] ester, reaction products with diethylamineDNELLong term Dermal3.33 mg/ kg bw/dayWorkersSystemic2-hydroxy-2-methylpropiophenoneDNELLong term Oral0.4 mg/kg bw/dayWorkersSystemicDNELLong term Dermal0.5 mg/kg lnhalationGeneral populationSystemicDNELLong term Dermal0.9 mg/m³General populationSystemicDNELLong term Dermal0.9 mg/m³General populationSystemicDNELLong term Dermal1.17 mg/m³SystemicDNELLong term Dermal0.4 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.9 mg/m³General populationSystemic populationDNELLong term Inhalation1.17 mg/m³WorkersSystemic populationDNELLong term Inhalation1.17 mg/m³Systemic populationSystemic populationUnmethyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylateDNELLong term Dermal Inhalation1.66 mg/ g bw/daySystemic SystemicDNELLong term Oral2.08 mg/General g bw/daySystemic Systemic		DNEL	Long term Dermal	17.5 mg/	Workers	Systemic	
with acrylic acidDNELLong term Inhalation1.17 mg/m³WorkersSystemic2-Propenoic acid, 1,1'-[(1-methyl- 1,2-ethanediyl)]is[oxy(methyl- 2,1-ethanediyl)]] ester, reaction products with diethylamineDNELLong term Dermal3.33 mg/ kg bw/dayWorkersSystemic2.hydroxy-2-methylpropiophenoneDNELLong term Oral23.51 mg/ m³WorkersSystemicDNELLong term Oral0.4 mg/kg bw/dayGeneral population opulationSystemicDNELLong term Dermal0.5 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.9 mg/m³General populationSystemic population0.Hethyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylateDNELLong term Dermal Inhalation1 mg/kg bw/dayWorkersSystemic population0.NELLong term Dermal1 mg/kg bw/dayWorkersSystemic populationSystemic population0.NELLong term Dermal1 mg/kg bw/dayWorkersSystemic Systemic0.NELLong term Dermal1 mg/kg bw/dayWorkersSystemic Systemic0.NELLong term Dermal1.66 mg/ kg bw/daySystemic SystemicSystemic Systemic0.NELLong term Oral2.08 mg/Seneral SystemicSystemic Systemic				kg bw/day			
2-Propenoic acid, 1,1'-[(1-methyl- 1,2-ethanediyl)bis[oxy(methyl- 2,1-ethanediyl)]] ester, reaction products with diethylamine 2-hydroxy-2-methylpropiophenone (1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylate (1-methyl-2,1-ethanediyl)] diacrylate DNEL Long term Dermal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL							
2-Propenoic acid, 1,1'-[(1-methyl-1,2-ethanediyl)bis[oxy(methyl-2,1-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)]] ester, reaction products with diethylamineDNELInhalation Long term Dermal3.33 mg/ kg bw/dayWorkersSystemic2-hydroxy-2-methylpropiophenoneDNELLong term Inhalation23.51 mg/ m³WorkersSystemicDNELLong term Oral0.4 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.5 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.5 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal0.5 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal0.5 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal1 mg/kg bw/dayWorkersSystemic populationDNELLong term Dermal1 mg/kg bw/dayWorkersSystemic populationDNELLong term Dermal1 mg/kg bw/dayWorkersSystemic 		DNEL	Long term	1.17 mg/m <sup>3</sup>	Workers	Systemic	
1,2-ethanediyl)bis[oxy(methyl- 2,1-ethanediyl)]] ester, reaction products with diethylamineNELLong term Inhalationkg bw/dayWorkersSystemic m32-hydroxy-2-methylpropiophenoneDNELLong term Oral0.4 mg/kg bw/dayGeneral populationSystemic population2-hydroxy-2-methylpropiophenoneDNELLong term Dermal0.5 mg/kg bw/dayGeneral populationSystemic population0.1 methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylateDNELLong term Dermal1 mg/kg bw/dayWorkersSystemic population0.1 methyl-2,1-ethanediyl)] diacrylateDNELLong term Oral1 mg/kg bw/dayWorkersSystemic population0.1 methyl-2,1-ethanediyl)] diacrylateDNELLong term Oral2.08 mg/General populationSystemic population0.1 methyl-2,1-ethanediyl)] diacrylateDNELLong term Oral2.08 mg/General generalSystemic population						-,	
2,1-ethanediyl)]] ester, reaction products with diethylamineDNELLong term Inhalation23.51 mg/ m³WorkersSystemic Systemic2-hydroxy-2-methylpropiophenoneDNELLong term Oral0.4 mg/kg bw/dayGeneral populationSystemic Systemic2-hydroxy-2-methylpropiophenoneDNELLong term Oral0.5 mg/kg bw/dayGeneral populationSystemic Systemic0.1DNELLong term Dermal0.5 mg/kg bw/dayGeneral populationSystemic Systemic0.1DNELLong term Inhalation0.9 mg/m³ BoreGeneral populationSystemic Systemic0.1DNELLong term Inhalation3.5 mg/m³ BoreWorkersSystemic Systemic0.1DNELLong term Dermal1 mg/kg Bw/dayWorkersSystemic Systemic0.1DNELLong term Dermal1.66 mg/ kg bw/dayGeneral SystemicSystemic Systemic0.1DNELLong term Oral2.08 mg/General GeneralSystemic Systemic		DNEL	Long term Dermal		Workers	Systemic	
products with diethylamineDNELLong term23.51 mg/ m³WorkersSystemic2-hydroxy-2-methylpropiophenoneDNELLong term Oral0.4 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal0.5 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal0.5 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal0.9 mg/m³General populationSystemic populationDNELLong term Inhalation3.5 mg/m³WorkersSystemic population0.1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylateDNELLong term Dermal Long term Oral1 mg/kg kg bw/dayGeneral populationDNELLong term Oral2.08 mg/General populationSystemic Systemic				kg bw/day			
2-hydroxy-2-methylpropiophenoneDNELLong term Inhalation23.51 mg/ m³WorkersSystemic Systemic2-hydroxy-2-methylpropiophenoneDNELLong term Oral0.4 mg/kg bw/dayGeneral populationSystemic SystemicDNELLong term Dermal0.5 mg/kg bw/dayGeneral populationSystemic SystemicDNELLong term Dermal0.5 mg/kg bw/dayGeneral populationSystemic SystemicDNELLong term Inhalation0.9 mg/m³General populationSystemic Systemic0.1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylateDNELLong term Dermal Long term Oral1 mg/kg bw/dayWorkersSystemic SystemicDNELLong term Dermal1.66 mg/ kg bw/dayGeneral populationSystemic SystemicDNELLong term Oral2.08 mg/General SystemicSystemic Systemic	,						
2-hydroxy-2-methylpropiophenone DNEL Long term Oral DNEL Long term Oral DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term D.9 mg/m <sup>3</sup> General population General population DNEL Long term D.9 mg/m <sup>3</sup> General population Systemic DNEL Long term D.9 mg/m <sup>3</sup> General population DNEL Long term D.9 mg/m <sup>3</sup> Workers Systemic DNEL Long term Dermal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL		DNEL	Long term	23.51 ma/	Workers	Systemic	
DNELLong term Dermalbw/day 0.5 mg/kg bw/daypopulation General populationSystemic SystemicDNELLong term Inhalation0.9 mg/m³General populationSystemic SystemicDNELLong term Inhalation3.5 mg/m³WorkersSystemic Systemic(1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylateDNELLong term Dermal Long term Oral1 mg/kg SystemicWorkersSystemic SystemicDNELLong term Dermal DNEL1 mg/kg Bw/dayWorkersSystemic SystemicDNELLong term Dermal DNEL1.66 mg/ kg bw/dayGeneral SystemicSystemic SystemicDNELLong term Oral2.08 mg/General SystemicSystemic Systemic							
DNELLong term Dermal0.5 mg/kg bw/dayGeneral populationSystemic populationDNELLong term0.9 mg/m³General populationSystemic populationDNELLong term3.5 mg/m³WorkersSystemic populationDNELLong term3.5 mg/m³WorkersSystemic populationDNELLong term Dermal1 mg/kg bw/dayWorkersSystemic Systemic(1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylateDNELLong term Dermal Long term Oral1.66 mg/ gov/dayGeneral populationSystemic SystemicDNELLong term Oral2.08 mg/General GeneralSystemic Systemic	2-hydroxy-2-methylpropiophenone	DNEL	Long term Oral			Systemic	
Image: constraint of the second system is the second system in the second system is the second sys		האיבי				0	
DNELLong term Inhalation0.9 mg/m³General populationSystemic population0.9 mg/m³General populationSystemic populationSystemic population0.1 mg/kg (1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylateDNELLong term Dermal Long term Dermal1 mg/kg bw/dayWorkersSystemic Systemic0.1 mg/kg (methyl-2,1-ethanediyl)] diacrylateDNELLong term Dermal Long term Oral1.66 mg/ kg bw/dayGeneral populationSystemic Systemic		DNEL	Long term Dermal			Systemic	
Inhalation Long term InhalationpopulationDNELDNELLong term Inhalation3.5 mg/m³WorkersSystemic(1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylateDNELLong term Dermal1 mg/kg bw/dayWorkersSystemicDNELLong term Dermal1.66 mg/ kg bw/dayGeneralSystemicDNELLong term Oral2.08 mg/GeneralSystemic		DNFI	Long term			Systemic	
DNELLong term Inhalation3.5 mg/m³WorkersSystemic(1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylateDNELLong term Dermal1 mg/kg bw/dayWorkersSystemicDNELLong term Dermal1.66 mg/ kg bw/dayGeneralSystemicDNELLong term Dermal1.66 mg/ kg bw/dayGeneralSystemicDNELLong term Oral2.08 mg/GeneralSystemic			-			- , , , , , , , , , , , , , , , , , , ,	
(1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylate DNEL Long term Dermal 1 mg/kg bw/day DNEL Long term Dermal 1.66 mg/ General Systemic kg bw/day population DNEL Long term Oral 2.08 mg/ General Systemic		DNEL	Long term	3.5 mg/m <sup>3</sup>		Systemic	
(1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylate DNEL Long term Dermal New General DNEL Long term Oral 2.08 mg/ General Systemic							
(1-methyl-1,2-ethanediyl)bis[oxy       DNEL       Long term Dermal       1.66 mg/       General       Systemic         (methyl-2,1-ethanediyl)] diacrylate       DNEL       Long term Oral       2.08 mg/       General       Systemic		DNEL	Long term Dermal		vvorkers	Systemic	
(methyl-2,1-ethanediyl)] diacrylate DNEL Long term Oral 2.08 mg/ General Systemic	1-methyl-1 2-ethanediyl\bis[oxy		l ong term Dermal		General	Systemic	
DNEL Long term Oral 2.08 mg/ General Systemic			Long torm Derma			Cysternie	
	, , , , , ,	DNEL	Long term Oral			Systemic	
kg bw/day population							
		DNEL		7.24 mg/m <sup>3</sup>		Systemic	
Inhalation         population           DNEL         Long term Dermal         1.7 mg/kg         Workers         Systemic				1.7 ma/ka		Systemic	
bivel Long term Dermai 1.7 mg/kg Workers Systemic		DINEL			VVUINCIS	Cysternic	

UVILUX 6790-03 - TS 6868 WHITE

Label No :40584

	DNEL	Long term	2.35 mg/m <sup>3</sup>	Workers	Systemic
	DINCL	Inhalation	2.55 mg/m	VUINEIS	Systemic
Diphenyl(2,4,6-trimethylbenzoyl)	DNEL	Long term Oral	83.3 µg/kg	General	Systemic
phosphine oxide	DINCE	Long term ordi	bw/day	population	Cysternio
	DNEL	Long term Dermal	83.3 µg/kg	General	Systemic
	DINCL	Long term Derma	bw/day	population	Oysternic
		Long torm		General	Sustamia
	DNEL	Long term	0.145 mg/	-	Systemic
		Inhalation	m <sup>3</sup>	population	
	DNEL	Long term Dermal	0.233 mg/	Workers	Systemic
		1	kg bw/day	\ <b>\ /</b>	O. un traversite
	DNEL	Long term	0.822 mg/	Workers	Systemic
		Inhalation	m <sup>3</sup>		
Fatty acids, C18-unsatd., dimers,	DNEL	Long term Dermal	0.33 mg/	Workers	Systemic
polymers with acrylic acid, bisphenol			kg bw/day		
A, epichlorohydrin and nonanoic acid					
	DNEL	Long term	1.18 mg/m <sup>3</sup>	Workers	Systemic
		Inhalation			
2,6-di-tert-butyl-p-cresol	DNEL	Long term Dermal	0.25 mg/	General	Systemic
			kg bw/day	population	
	DNEL	Long term Dermal	0.5 mg/kg	Workers	Systemic
		-	bw/day		
	DNEL	Long term Oral	0.25 mg/	General	Systemic
		Ŭ	kg bw/day	population	,
	DNEL	Long term	0.435 mg/	General	Systemic
		Inhalation	m <sup>3</sup>	population	- ,
	DNEL	Long term	1.76 mg/m <sup>3</sup>	Workers	Systemic
	DITE	Inhalation		Tronkoro -	eyetenne
Cyclohexane	DNEL	Long term Oral	59.4 mg/	General	Systemic
Oyolonexane	DINCE	Long term ordi	kg bw/day	population	Cysternio
	DNEL	Long term	206 mg/m <sup>3</sup>	General	Local
	DNEL	Inhalation	200 mg/m		LUCAI
	DNEL		$206 mg/m^{3}$	population General	Svetemie
	DNEL	Long term	206 mg/m <sup>3</sup>		Systemic
		Inhalation	440	population	Lanal
	DNEL	Short term	412 mg/m <sup>3</sup>	General	Local
		Inhalation		population	
	DNEL	Short term	412 mg/m <sup>3</sup>	General	Systemic
		Inhalation		population	
	DNEL	Short term	700 mg/m <sup>3</sup>	Workers	Local
		Inhalation			
	DNEL	Long term	700 mg/m <sup>3</sup>	Workers	Local
		Inhalation			
	DNEL	Short term	700 mg/m <sup>3</sup>	Workers	Systemic
		Inhalation			
	DNEL	Long term	700 mg/m <sup>3</sup>	Workers	Systemic
		Inhalation	-		
	DNEL	Long term Dermal	1186 mg/	General	Systemic
		Ŭ	kg bw/day	population	,
	DNEL	Long term Dermal	2016 mg/	Workers	Systemic
			kg bw/day		- ,
2,6-di-tert-butyl-p-cresol	DNEL	Long term Dermal	0.25 mg/	General	Systemic
	DILLE	Long tonin Donnar	kg bw/day	population	Cyclonno
	DNEL	Long term Dermal	0.5 mg/kg	Workers	Systemic
		Long term Dermal	bw/day	TTOINE S	Gysternic
		Long torm Oral		General	Svetomia
	DNEL	Long term Oral	0.25 mg/	General	Systemic
		Long to me	kg bw/day	population	Constant in
	DNEL	Long term	0.435 mg/	General	Systemic
	<b>D</b>	Inhalation	m <sup>3</sup>	population	
	DNEL	Long term	1.76 mg/m <sup>3</sup>	Workers	Systemic
	1	Inhalation	1		1

#### **PNECs**

No PNECs available

### 8.2 Exposure controls

Date of issue/Date of revision : UVILUX 6790-03 - TS 6868 WHITE

: 24/10/2022 Date of previous issue

: No previous validation

# **SECTION 8: Exposure controls/personal protection**

	re controls/personal protection
Appropriate engineering controls	<ul> <li>If user operations generate dust, fumes, gas, vapour or mist, use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits.</li> </ul>
Individual protection meas	<u>ures</u>
Hygiene measures	: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.
Eye/face protection	: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles and/or face shield. If inhalation hazards exist, a full-face respirator may be required instead.
Skin protection	
Hand protection	: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.
	Recommendations : Wear suitable gloves tested to EN374.
	< 1 hour (breakthrough time): Nitrile gloves. thickness > 0.3 mm
	1 - 4 hours (breakthrough time): $4H$ / Silver Shield® gloves.
Body protection	: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Other skin protection	<ul> <li>Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.</li> </ul>
Respiratory protection	: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.
	Filter type: A Filter type (spray application): A P
Environmental expective	
Environmental exposure controls	: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

# **SECTION 9: Physical and chemical properties**

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

#### 9.1 Information on basic physical and chemical properties

Appearance	-
Physical state	: Liquid.
Colour	: White.
Odour	: Slight
Odour threshold	: Not available.
Melting point/freezing point	: Not available.
Initial boiling point and boiling range	:

Ingredient name	c	°C	°F	Method	
(1-methyl-1,2-ethanediyl)bis[oxy(methyl- 2,1-ethanediyl)] diacrylate	>	•120	>248		
Propylidynetrimethanol, ethoxylated, este acrylic acid	ers with >	•391	>735.8	OECD 103	
- Flammability (solid, gas)	: Not availa	able.			
Jpper/lower flammability or explosive limits		ot applicable ot applicable			
Flash point	: Closed cu	up: >100°C (	>212°F)		
Auto-ignition temperature	:				
Ingredient name	c	°C	°F	Method	
Hexamethylene diacrylate	2	235	455	DIN 51794	
Dipropylenglycol diacrylate	2	240	464	DIN 51794	
Decomposition temperature	: Not availa	able.	·	· · · ·	
эΗ	: Not availa	able.			
/iscosity	: Not availa	able.			
Solubility(ies)	:				
Not available.					
Solubility in water	: Not availa	able.			
Partition coefficient: n-octanol/ water	: Not applie	cable.			
Vapour pressure	:				

	Va	Vapour Pressure at 20°C			Vapour pressure at 50°C			
Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	Method		
Hexamethylene diacrylate	0	0	EU A.4					
Dipropylenglycol diacrylate	0	0	OECD 104					
Relative density	: Not	available.						
Density	: 1.2	g/cm³						
/apour density	: Not	available.						
Explosive properties	: Not	available.						
<b>Oxidising properties</b>	: Not	available.						
Particle characteristics								
Median particle size	: Not	applicable.						
ledian particle size	: Not	applicable.						

SECTION 10: Stabilit	SECTION 10: Stability and reactivity						
10.1 Reactivity	: No specific test data related to reactivity available for this product or its ingredients.						
10.2 Chemical stability	: The product is stable.						
10.3 Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur.						
10.4 Conditions to avoid	: No specific data.						
10.5 Incompatible materials	: No specific data.						
10.6 Hazardous decomposition products	: Under normal conditions of storage and use, hazardous decomposition products should not be produced.						

Date of issue/Date of revision	: 24/10/2022	Date of previous issue	: No previous validation	Version :	1 <b>10/18</b>
UVILUX 6790-03 - TS 6868 WHIT	E			Label No :40	)584

# **SECTION 11: Toxicological information**

### 11.1 Information on toxicological effects

### Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
Hexamethylene diacrylate	LD50 Oral	Rat	5 g/kg	-
Dipropylenglycol diacrylate	LD50 Oral	Rat	4600 mg/kg	-
Propylidynetrimethanol, ethoxylated, esters with acrylic acid	LD50 Dermal	Rabbit	>13 g/kg	-
2-hydroxy- 2-methylpropiophenone	LD50 Dermal	Rat	6929 mg/kg	-
	LD50 Oral	Rat	1694 mg/kg	-
(1-methyl-1,2-ethanediyl)bis [oxy(methyl-2,1-ethanediyl)] diacrylate	LD50 Oral	Rat	6200 mg/kg	-
2,6-di-tert-butyl-p-cresol Cyclohexane 2,6-di-tert-butyl-p-cresol	LD50 Oral LD50 Oral LD50 Oral	Rat Rat Rat	890 mg/kg 6240 mg/kg 890 mg/kg	- - -

# Conclusion/Summary

: Based on available data, the classification criteria are not met.

#### Acute toxicity estimates

Route	ATE value		
Oral	53943.65 mg/kg		

### Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation
Hexamethylene diacrylate	Skin - Severe irritant	Rabbit	-	24 hours 500	-
				mg	
Dipropylenglycol diacrylate	Eyes - Severe irritant	Rabbit	-	100 mg	-
	Skin - Severe irritant	Rabbit	-	500 mg	-
Propylidynetrimethanol, ethoxylated, esters with acrylic acid	Eyes - Moderate irritant	Rabbit	-	100 mg	-
-	Skin - Moderate irritant	Rabbit	-	500 mg	-
titanium dioxide	Skin - Mild irritant	Human	-	72 hours 300 ug l	-
(1-methyl-1,2-ethanediyl)bis [oxy(methyl-2,1-ethanediyl)] diacrylate	Eyes - Severe irritant	Rabbit	-	24 hours 100 uL	-
-	Skin - Moderate irritant	Rabbit	-	500 mg	-
Polyethylene wax	Eyes - Mild irritant	Rabbit	-	24 hours 100 mg	-
	Eyes - Mild irritant	Rabbit	-	50 %	-
	Skin - Mild irritant	Rabbit	-	24 hours 500 mg	-
	Skin - Moderate irritant	Rabbit	-	500 mg	-
2,6-di-tert-butyl-p-cresol	Eyes - Moderate irritant	Rabbit	-	24 hours 100 mg	-
	Skin - Mild irritant	Human	-	48 hours 500 mg	-
	Skin - Moderate irritant	Rabbit	-	48 hours 500 mg	-
2,6-di-tert-butyl-p-cresol	Eyes - Moderate irritant	Rabbit	-	24 hours 100	-
	Skin - Mild irritant	Human	-	48 hours 500 mg	-
	Skin - Moderate irritant	Rabbit	-	48 hours 500 mg	-
Conclusion/Summary	: Causes skin irritation.				
Sensitisation					
Conclusion/Summary	: May cause an allergic skin	reaction.			
<u>Autagenicity</u>	· · · · · · · · · · · · · · · · · · ·				

UVILUX 6790-03 - TS 6868 WHITE

# **SECTION 11: Toxicological information**

#### **Conclusion/Summary**

y : Based on available data, the classification criteria are not met.

#### **Carcinogenicity**

It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantities leading to significant impairment of particle clearance mechanisms in the lung.

- **Conclusion/Summary** : Based on available data, the classification criteria are not met.
- **Reproductive toxicity**
- **Conclusion/Summary**

: Based on available data, the classification criteria are not met.

#### **Teratogenicity**

**Conclusion/Summary** : Based on available data, the classification criteria are not met.

Specific target organ toxicity (single exposure)

Product/ingredient name	Category	Route of exposure	Target organs
(1-methyl-1,2-ethanediyl)bis[oxy(methyl-2,1-ethanediyl)] diacrylate	Category 3	-	Respiratory tract irritation
Cyclohexane	Category 3	-	Narcotic effects

#### Specific target organ toxicity (repeated exposure)

Not available.

#### Aspiration hazard

Product/ingredient name	Result
Cyclohexane	ASPIRATION HAZARD - Category 1

Information on likely routes of exposure	1	Not available.
Potential acute health effects		
Eye contact	:	Causes serious eye damage.
Inhalation	:	No known significant effects or critical hazards.
Skin contact	:	Causes skin irritation. May cause an allergic skin reaction.
Ingestion	:	No known significant effects or critical hazards.

#### Symptoms related to the physical, chemical and toxicological characteristics

Eye contact	: Adverse symptoms may include the following: pain watering redness
Inhalation	: No specific data.
Skin contact	: Adverse symptoms may include the following: pain or irritation redness blistering may occur
Ingestion	: Adverse symptoms may include the following: stomach pains

Delayed and immediate effec	s as well as chronic effects from short and long-term exposure
<u>Short term exposure</u>	
Potential immediate effects	: Not available.
Potential delayed effects	: Not available.
Long term exposure	
Potential immediate effects	: Not available.
Potential delayed effects	

Potential chronic health effects

Date of issue/Date of revision	: 24/10/2022	Date of previous issue	: No previous valida
UVILUX 6790-03 - TS 6868 WHIT	E		

# **SECTION 11: Toxicological information**

Not available.

Conclusion/Summary	: Not available.
General	: Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.
Carcinogenicity	: No known significant effects or critical hazards.
Mutagenicity	: No known significant effects or critical hazards.
Reproductive toxicity	: No known significant effects or critical hazards.

#### **Other information**

: Not available.

# **SECTION 12: Ecological information**

Product/ingredient name	Result	Species	Exposure
Hexamethylene diacrylate	EC50 1.09 mg/l	Algae - Algae - Selenastrum capricornutum	72 hours
	EC50 2.7 mg/l	Daphnia - Daphnia - Daphnia magna	48 hours
	LC50 0.38 mg/l	Fish - Oryzias latipes	96 hours
	NOEC 0.5 mg/l	Algae - Álgae - Desmodesmus subspicatus	72 hours
	NOEC 0.14 mg/l	Daphnia - Daphnia - Daphnia magna	21 days
	NOEC 0.072 mg/l	Fish - Oryzias latipes	96 hours
titanium dioxide	Acute LC50 3 mg/l Fresh water	Crustaceans - Water flea - Ceriodaphnia dubia - Neonate	48 hours
	Acute LC50 6.5 mg/l Fresh water	Daphnia - Water flea - Daphnia pulex - Neonate	48 hours
	Acute LC50 >1000000 μg/l Marine water	Fish - Mummichog - Fundulus heteroclitus	96 hours
2,6-di-tert-butyl-p-cresol	Acute EC50 1440 μg/l Fresh water	Daphnia - Water flea - Daphnia pulex - Neonate	48 hours
Cyclohexane	Acute LC50 4530 µg/l Fresh water	, Fish - Fathead minnow - Pimephales promelas	96 hours
2,6-di-tert-butyl-p-cresol	Acute EC50 1440 µg/l Fresh water	Daphnia - Water flea - Daphnia pulex - Neonate	48 hours

### 12.2 Persistence and degradability

Conclusion/Summary	: This product has not been tested for	r biodegradation.	
Product/ingredient name	Aquatic half-life	Photolysis	Biodegradability
Propylidynetrimethanol, ethoxylated, esters with acrylic acid	-	-	Readily

#### 12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
Hexamethylene diacrylate	2.81	-	low
Dipropylenglycol diacrylate	0.01 to 0.39	-	low
Propylidynetrimethanol, ethoxylated, esters with acrylic acid	2.89	-	low
4,4'-Isopropylidenediphenol, oligomeric reaction products with 1-chloro- 2,3-epoxypropane, esters with acrylic acid	1.6 to 3	-	low
2-hydroxy-	1.62	-	low
Date of issue/Date of revision	: 24/10/2022	Date of previous issue	: No previous validation Version : 1 13/18
UVILUX 6790-03 - TS 6868 WI	HITE		Label No :40584

SECTION 12: Ecological information			
2-methylpropiophenone (1-methyl-1,2-ethanediyl)bis [oxy(methyl-2,1-ethanediyl)] diacrylate	2	-	low
Diphenyl (2,4,6-trimethylbenzoyl) phosphine oxide	-	53 to 72	low

12.4 Mobility in soil	
Soil/water partition coefficient (Koc)	: Not available.
Mobility	: Not available.

#### 12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

**12.6 Other adverse effects** : No known significant effects or critical hazards.

# **SECTION 13: Disposal considerations**

13.1 Waste treatment meth	5	
Product		
Methods of disposal	: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation a any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed untreated to the sewer unless fully compliant with the requirements of all authoritie with jurisdiction.	of
Hazardous waste	: Yes.	
European waste catalogue (EWC)	: 080111*	
Packaging		
Methods of disposal	: The generation of waste should be avoided or minimised wherever possible. Was packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.	te
Special precautions	: This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.	

# **SECTION 14: Transport information**

	ADR/RID	ADN	IMDG	ΙΑΤΑ
14.1 UN number	UN3082	UN3082	UN3082	UN3082
14.2 UN proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (PAINT)	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (PAINT)	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (PAINT)	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (PAINT)
14.3 Transport hazard class(es)	9	9	9	9
14.4 Packing group	III	111	111	111
Date of issue/Date of rev UVILUX 6790-03 - T		Date of previous issue	: No previous validation	Version         : 1         14/18           Label No         :40584

SECTION 14: Transport information							
14.5 Environmental hazards	Yes.			Yes.	Yes.		Yes.
Additional informati	ion				·		
ADR/RID				ovided the packagings to 4.1.1.8.			nsported in sizes of ≤5 L ns of 4.1.1.1, 4.1.1.2
ADN				ovided the packagings			nsported in sizes of ≤5 L ns of 4.1.1.1, 4.1.1.2
IMDG				ovided the packagings			nsported in sizes of ≤5 L ns of 4.1.1.1, 4.1.1.2
ΙΑΤΑ			or ≤5 kg, pr	ct is not regulated as a ovided the packagings and 5.0.2.8.			nsported in sizes of ≤5 L ns of 5.0.2.4.1,
14.6 Special precaut user	ions for		upright and		ersons transp		sed containers that are oduct know what to do in
14.7 Transport in bu according to IMO instruments	lk	:	Not relevan	t/applicable due to nat	ure of the pro	duct.	

### **SECTION 15: Regulatory information**

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture <u>UK (GB) /REACH</u>

#### Annex XIV - List of substances subject to authorisation

#### Annex XIV

None of the components are listed.

#### Substances of very high concern

None of the components are listed.

#### **Ozone depleting substances**

Not listed.

#### **Prior Informed Consent (PIC)**

Not listed.

#### Persistent Organic Pollutants

Not listed.

#### Annex XVII - Restrictions : Not applicable.

on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

#### Seveso Directive

This product is controlled under the Seveso Directive.

#### Danger criteria

#### Category

E1

#### EU regulations

Date of issue/Date of revision UVILUX 6790-03 - TS 6868 WHITE

SECTION 15: Regulatory information
Industrial emissions : Not listed (integrated pollution prevention and control) - Air
Industrial emissions : Not listed (integrated pollution prevention and control) - Water
International regulations
Chemical Weapon Convention List Schedules I, II & III Chemicals
Not listed.
Montreal Protocol Not listed.
Stockholm Convention on Persistent Organic Pollutants Not listed.
Rotterdam Convention on Prior Informed Consent (PIC) Not listed.
UNECE Aarhus Protocol on POPs and Heavy Metals
Not listed.
<b>15.2 Chemical safety</b> : This product contains substances for which Chemical Safety Assessments are stil required.

### **SECTION 16: Other information**

Indicates information that has changed from previously issued version.

Abbreviations and	: ATE = Acute Toxicity Estimate
acronyms	GB CLP = UK CLP (EC No 1272/2008) on the Classification, Labelling and
	Packaging of Substances and Mixtures as amended by (EU Exit) Regulations 2019
	No. 720 and amendments
	DMEL = Derived Minimal Effect Level
	DNEL = Derived No Effect Level
	EUH statement = GB CLP-specific Hazard statement
	N/A = Not available
	PBT = Persistent, Bioaccumulative and Toxic
	PNEC = Predicted No Effect Concentration
	RRN = REACH Registration Number
	SGG = Segregation Group
	vPvB = Very Persistent and Very Bioaccumulative

#### Procedure used to derive the classification

Classification	Justification
Skin Irrit. 2, H315	Calculation method
Eye Dam. 1, H318	Calculation method
Skin Sens. 1, H317	Calculation method
Aquatic Acute 1, H400	Calculation method
Aquatic Chronic 2, H411	Calculation method

#### Full text of abbreviated H statements

H225	Highly flammable liquid and vapour.
H302	Harmful if swallowed.
H304	May be fatal if swallowed and enters airways.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H318	Causes serious eye damage.
H319	Causes serious eye irritation.
H335	May cause respiratory irritation.
H336	May cause drowsiness or dizziness.

H351 Su	Suspected of causing cancer.			
	uspected of damaging fertility.			
	ry toxic to aquatic life.			
	ery toxic to aquatic life with long lasting effects.			
	oxic to aquatic life with long lasting effects.			
H412 Ha	Harmful to aquatic life with long lasting effects.			
Full text of classific	ations			
Acute Tox. 4	ACUTE TOXICITY - Category 4			
Aquatic Acute 1	SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1			
Aquatic Chronic 1	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1			
Aquatic Chronic 2	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2			
Aquatic Chronic 3	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3			
Asp. Tox. 1	ASPIRATION HAZARD - Category 1			
Carc. 2	CARCINOGENICITY - Category 2			
Eye Dam. 1	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1			
Eye Irrit. 2	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2			
Flam. Liq. 2	FLAMMABLE LIQUIDS - Category 2			
Repr. 2	REPRODUCTIVE TOXICITY - Category 2			
Skin Irrit. 2	SKIN CORROSION/IRRITATION - Category 2			
Skin Sens. 1	SKIN SENSITISATION - Category 1			
Skin Sens. 1B	SKIN SENSITISATION - Category 1B			
STOT SE 3	SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE - Category 3			

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the

demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a guarantee of the product's properties.

: No previous validation

: 1

revision

Version

Date of previous issue

Notice to reader

Date of issue/Date of revision : UVILUX 6790-03 - TS 6868 WHITE